Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Genmark Diagnostics on Wednesday, setting a price target of $19, which is approximately 23.22% above the present share price of $15.42.
Matson expects Genmark Diagnostics to post earnings per share (EPS) of -$0.12 for the third quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in GenMark (NASDAQ:GNMK), with an average price target of $17.
The analysts price targets range from a high of $19 to a low of $15.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $38.74 million and a net profit of -$5.01 million. The company's market cap is $1.09 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 7.2% and a 57.18% success rate.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the provision of multiplex molecular diagnostic solutions. Its products include ePlex and XT-8. The company was founded by Jon Faiz Kayyemin 1993 and is headquartered in Carlsbad, CA.